NASDAQ$SMTI
Sanara MedTech Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Announced strategic, operational and financial results for the quarter and full year ended December 31, 2022.
Sanara MedTech Inc. reported record sales results in both the fourth quarter and the full year, driven by the expansion of its sales team's geographic coverage, increased average sales per facility, and an expanded product line.
- Expanded geographic coverage of sales team.
- Increased average sales per facility.
- Offered an expanded line of products.
- Achieved record sales results in both the fourth quarter and the full year.
Headline financials
Revenue & EPS history
Sanara MedTech · Revenue · Quarterly
$15.3M
Revenue by segment
Sanara MedTech · $31.6M total across 2 segments · Q2 2023
- Soft tissue repair$15.8M—50.0%
- Bone fusion products$15.8M—50.0%
Forward guidance
The company is focused on improving patient outcomes through evidence-based healing solutions and is actively seeking to expand within its six focus areas of wound and skin care for the acute, post-acute, and surgical markets.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+0.2%
Avg return
Earnings day
-2.3%
Avg return
5 days after
+1.0%
Avg return
30 days after
34%
22 / 64 earnings
Positive
+28.6%
Q4 2014
Best reaction
-25.0%
Q3 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +13.0% | +17.3% | — | |
| Q4 2025 | -0.3% | -7.5% | +4.3% | |
| Q3 2025 | -23.4% | -24.9% | -7.6% | |
| Q1 2025 | -9.0% | -11.2% | -17.9% | |
| Q4 2024 | -12.6% | -15.4% | -10.4% | |
| Q3 2024 | +6.3% | -1.0% | +2.5% | |
| Q2 2024 | +14.9% | +16.3% | +20.2% | |
| Q1 2024 | -5.0% | -2.9% | -0.5% | |
| Q4 2023 | -1.8% | -1.1% | -13.1% | |
| Q3 2023 | +18.8% | +15.3% | +37.5% | |
| Q2 2023 | -12.5% | -13.6% | -22.6% | |
| Q1 2023 | -5.0% | -9.2% | -5.9% | |
| Q4 2022 | -0.1% | -4.1% | +17.9% | |
| Q3 2022 | +4.1% | +7.2% | +3.2% | |
| Q2 2022 | +1.2% | -1.7% | +13.4% | |
| Q1 2022 | +5.0% | +2.3% | -12.2% | |
| Q4 2021 | +2.5% | +10.7% | -10.9% | |
| Q3 2021 | -1.6% | -2.2% | -15.8% | |
| Q2 2021 | -8.3% | -12.4% | -14.5% | |
| Q1 2021 | +5.2% | +14.9% | +28.7% | |
| Q4 2020 | +14.5% | +6.8% | -4.5% | |
| Q3 2020 | -4.5% | -4.3% | +15.7% | |
| Q2 2020 | +9.8% | +13.7% | +37.2% | |
| Q1 2020 | -20.7% | -18.2% | +28.8% | |
| Q4 2019 | -4.3% | +7.3% | +30.9% | |
| Q3 2019 | -3.9% | -5.7% | +5.1% | |
| Q2 2019 | -11.5% | -20.1% | -17.2% | |
| Q1 2019 | +0.0% | -16.7% | -16.7% | |
| Q4 2018 | +0.0% | -16.7% | -16.7% | |
| Q3 2018 | +0.0% | +0.0% | +0.0% | |
| Q2 2018 | -10.0% | -10.0% | -30.0% | |
| Q1 2018 | +20.0% | +0.0% | +20.0% | |
| Q4 2017 | +20.0% | +0.0% | +20.0% | |
| Q3 2017 | +0.0% | +0.0% | -14.3% | |
| Q2 2017 | +0.0% | +16.7% | +16.7% | |
| Q1 2017 | +0.0% | +0.0% | -22.2% | |
| Q4 2016 | +0.0% | +0.0% | -10.0% | |
| Q3 2016 | -20.0% | -20.0% | +0.0% | |
| Q2 2016 | +20.0% | +0.0% | +0.0% | |
| Q1 2016 | +0.0% | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +11.1% | — | — | |
| Q4 2014 | +28.6% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +14.3% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +16.7% | — | — | |
| Q4 2012 | -12.5% | — | — | |
| Q3 2012 | -16.7% | — | — | |
| Q2 2012 | +6.7% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | -4.3% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | -10.3% | — | — | |
| Q1 2011 | -11.1% | — | — | |
| Q4 2010 | +3.1% | — | — | |
| Q3 2010 | -25.0% | — | — | |
| Q2 2010 | +2.9% | — | — | |
| Q1 2010 | +5.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro